Byoung-Chul Cho
Overview
Explore the profile of Byoung-Chul Cho including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
722
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ang Y, Zhao X, Reungwetwattana T, Cho B, Liao B, Yeung R, et al.
Cancers (Basel)
. 2023 Oct;
15(20).
PMID: 37894366
Epidermal growth factor receptor () T790M mutations drive resistance in 50% of patients with advanced non-small cell lung cancer (NSCLC) who progress on first/second generation (1G/2G) EGFR tyrosine kinase inhibitors...
2.
Prabhash K, Tan D, Soo R, Sitthideatphaiboon P, Chen Y, Voon P, et al.
Front Oncol
. 2023 Apr;
13:1117348.
PMID: 37051534
Introduction: Stage III non-small cell lung cancer (NSCLC) is a heterogeneous disease requiring multimodal treatment approaches. KINDLE-Asia, as part of a real world global study, evaluated treatment patterns and associated...
3.
Mitsudomi T, Tan D, Yang J, Ahn M, Batra U, Cho B, et al.
J Thorac Oncol
. 2022 Nov;
18(4):436-446.
PMID: 36379356
Introduction: Most published guidelines for genomic biomarker testing in NSCLC reflect the disease epidemiology and treatments readily available in Europe and North America. Nevertheless, 60% of annual global NSCLC cases...
4.
Jazieh A, Onal H, Tan D, Soo R, Prabhash K, Kumar A, et al.
J Thorac Oncol
. 2021 May;
16(10):1733-1744.
PMID: 34051381
Introduction: Stage III NSCLC is a heterogeneous disease requiring a multimodal management approach. We conducted a real-world, global study to characterize patients, treatment patterns, and their associated clinical outcomes for...
5.
Garassino M, Cho B, Kim J, Mazieres J, Vansteenkiste J, Lena H, et al.
Lung Cancer
. 2020 Jul;
147:137-142.
PMID: 32702570
Introduction: In the phase II ATLANTIC study, durvalumab provided durable responses with acceptable tolerability in heavily pretreated patients with advanced NSCLC, across three independent patient cohorts defined by EGFR/ALK status...
6.
Leighl N, Karaseva N, Nakagawa K, Cho B, Gray J, Hovey T, et al.
Eur J Cancer
. 2019 Dec;
125:49-57.
PMID: 31838405
Background: In the FLAURA trial, osimertinib demonstrated superior progression-free survival and a favorable toxicity profile to erlotinib or gefitinib as initial therapy in patients with EGFR-mutated advanced non-small-cell lung cancer....
7.
Garassino M, Cho B, Kim J, Mazieres J, Vansteenkiste J, Lena H, et al.
Lancet Oncol
. 2018 Mar;
19(4):521-536.
PMID: 29545095
Background: Immune checkpoint inhibitors are a new standard of care for patients with advanced non-small-cell lung cancer (NSCLC) without EGFR tyrosine kinase or anaplastic lymphoma kinase (ALK) genetic aberrations (EGFR-/ALK-),...
8.
Soo R, Kim H, Asuncion B, Fazreen Z, Omar M, Herrera M, et al.
Lung Cancer
. 2017 Feb;
105:17-22.
PMID: 28236980
Objectives: To characterize the expression of PD-L1, PD-1, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and T-cell immunoglobulin and mucin-domain containing-3 (TIM3) in epidermal growth factor receptor (EGFR) mutant non-small cell lung...
9.
Tan C, Cho B, Soo R
Lung Cancer
. 2016 Feb;
93:59-68.
PMID: 26898616
Since the discovery of sensitizing EGFR mutations as a predictive marker of sensitivity to EGFR tyrosine kinase inhibitors (TKIs), the field of targeted therapy in non-small cell lung cancer (NSCLC)...
10.
Ahn M, Kim S, Cho B, Ahn J, Lee D, Sun J, et al.
Oncologist
. 2015 May;
20(5):570.
PMID: 25956899
No abstract available.